术中放疗剂量递增治疗新诊断胶质母细胞瘤的III期随机对照试验
INTRAGO-II是一项开放标签、多中心、随机对照III期试验,评估在标准治疗基础上加用术中放疗(30 Gy)能否改善新诊断胶质母细胞瘤患者的结局。结论认为术中放疗即时、空间精确的剂量递增未能改善结局,对可切除胶质母细胞瘤进一步局部剂量强化提出质疑。
核心结论
- 在标准治疗基础上加用术中放疗(30 Gy)未能改善新诊断胶质母细胞瘤患者的无进展生存期。
- 研究结果对可切除胶质母细胞瘤进一步局部剂量强化的价值提出质疑。
研究设计与样本
- INTRAGO-II为开放标签、多中心、随机对照III期试验,纳入18-80岁、幕上胶质母细胞瘤、可切除强化肿瘤且KPS≥60%的患者。
- 来自巴西、加拿大、中国、德国、西班牙、韩国和美国18个中心的患者按1:1随机分配至术中放疗组(术中接受30 Gy千伏级术中放疗)或标准治疗组(仅手术),按年龄、KPS和残留肿瘤分层。
- 术后治疗为外照射放疗60 Gy同步替莫唑胺(75 mg/m2),后续六个周期辅助替莫唑胺(150-200 mg/m2,每28天第1-5天)。
- 主要终点为全分析集经盲法中心审查确认的中位无进展生存期;全分析集共298例(术中放疗组161例,标准治疗组137例)。
主要发现
- 严重不良事件:术中放疗组105例(65%)患者共252起,标准治疗组72例(53%)患者共142起;其中可能治疗相关事件分别为40例(38%)患者65起(26%)和19例(26%)患者27起(19%)。
- 所有报告的5级不良事件中,术中放疗组14起(中枢神经系统毒性2起、心肌梗死2起、脓毒症2起,以及心脏骤停、发热、肺部感染、骨折、术后出血、肿瘤、血肿和未特指死亡各1起),标准治疗组6起(肺部感染2起,多器官衰竭、脑炎、肿瘤和膀胱炎各1起),均归因于特定CTCAE术语。
关键数值与推荐
- 术中放疗剂量为30 Gy千伏级术中放疗,术后外照射放疗60 Gy同步替莫唑胺75 mg/m2,辅助替莫唑胺150-200 mg/m2每28天第1-5天共六周期。
临床怎么用
- 对于可切除的新诊断胶质母细胞瘤,不推荐在标准治疗基础上常规加用术中放疗进行局部剂量强化。
- 术中放疗增加严重不良事件和3-4级癫痫风险,临床决策时需权衡毒性。
- 局部复发仍是主要失败模式,需探索其他治疗策略而非单纯局部剂量递增。
局限性
- 研究未收集种族和族裔数据。
- 该研究正在进行中但已停止招募,结果基于全分析集298例患者。
- 开放标签设计可能影响不良事件报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite maximal safe resection and chemoradiotherapy, most glioblastomas recur locally. We aimed to evaluate whether additional intraoperative radiotherapy compared with standard of care improves outcomes in patients with newly diagnosed glioblastoma. METHODS: INTRAGO-II was an open-label, multicentre, randomised, controlled, phase 3 trial enrolling patients aged 18-80 years with supratentorial glioblastoma amenable to resection of the contrast enhancing tumour with Karnofsky performance score (KPS) of ≥60%. Patients from 18 centres in Brazil, Canada, China, Germany, Spain, South Korea, and the USA were randomly assigned (1:1) intraoperatively to receive additional kilovoltage intraoperative radiotherapy with 30 Gy (intraoperative radiotherapy group) or surgery alone (standard-of-care group), stratified by age, KPS, and residual tumour. Postoperative treatment consisted of external-beam radiotherapy to 60 Gy with concurrent temozolomide (75 mg/m2), followed by six adjuvant cycles of temozolomide (150-200 mg/m2, days 1-5 every 28 days). The primary endpoint was median progression-free survival in the full-analysis set, confirmed by masked, centralised review. This ongoing study is closed to recruitment and is registered with ClinicalTrials.gov, NCT02685605. FINDINGS: Between Dec 9, 2016, and June 17, 2024, of 411 patients assessed for eligibility, 314 were randomly assigned. The full-analysis set comprised 298 patients (intraoperative radiotherapy, n=161; standard-of-care, n=137), of whom 127 (43%) patients were female and 171 (57%) were male. Data on race and ethnicity were not collected. At a median follow-up of 17·2 months (IQR 10·5-27·1), median progression-free survival was 11·0 months (95% CI 9·2-12·6) in the intraoperative radiotherapy group versus 11·4 months (9·7-13·9) in the standard-of-care group (hazard ratio [HR] 1·1, 95% CI 0·85-1·44; p=0·47). Local recurrence was the predominant pattern of failure in both groups (76 [72%] in the intraoperative radiotherapy group vs 60 [71%] in the standard-of-care group, p=0·87). The most common grade 3-4 adverse events were seizure (21 [13%] in the intraoperative radiotherapy group vs nine [7%] in the standard-of-care group), radiation necrosis (11 [7%] vs three [2%]; p=0·06), thrombocytopenia (seven [4%] vs 11 [8%]), and muscle weakness (12 [7%] vs 19 [14%]). In total, 252 serious adverse events occurred in 105 (65%) patients in the intraoperative radiotherapy group and 142 serious adverse events in 72 (53%) patients in the standard-of-care group. Of these, 65 (26%) events in 40 (38%) patients in the intraoperative radiotherapy group and 27 (19%) events in 19 (26%) patients in the standard-of-care group were considered possibly related to the treatment. Of all grade five adverse events reported, 14 in the intraoperative radiotherapy group (CNS toxicity [n=2], myocardial infarction [n=2], sepsis [n=2], and one each cardiac arrest, fever, lung infection, fracture, postoperative haemorrhage, neoplasm, haematoma, and not otherwise specified death) and six in the standard-of-care group (lung infection [n=2], and one each multiorgan failure, encephalitis, neoplasm, and cystitis) were attributable to specific CTCAE terms. INTERPRETATION: Instant, spatially precise dose escalation with intraoperative radiotherapy added to standard of care did not improve outcomes, questioning the value of further local dose intensification in resectable glioblastoma. FUNDING: Universities of Heidelberg and Bonn, Carl Zeiss Meditec, Deutsche Forschungsgemeinschaft.
引用
- Giordano FA, Ganslandt O, Münter MW, et al. Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2026. PMID: 42372746. doi:10.1016/S1470-2045(26)00235-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。